Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lung Neoplasms 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Hairy Cell 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Ependymoma 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1

Interventions

Cyclophosphamide 35Temozolomide 33Filgrastim 26Etoposide 26Carboplatin 25Vincristine 22Cisplatin 22Radiotherapy 20Magnetic Resonance Spectroscopy 18Thiotepa 14Irinotecan 13Granulocyte Colony-Stimulating Factor 12Peripheral Blood Stem Cell Transplantation 11Lomustine 11Specimen Handling 9Radiation 9Melphalan 9etoposide phosphate 8Topotecan 8Methotrexate 8X-Rays 7Platinum 7Phantoms, Imaging 7sonidegib 6Biopsy 61,2-diaminocyclohexaneplatinum II citrate 6sargramostim 5palbociclib 5Nuclear Medicine Department, Hospital 5HhAntag691 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × Histamine Antagonists × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡